#United States #Burlington #financial results #revenue growth #Labcorp Holdings

Labcorp Reports 2024 Fourth Quarter and Full Year Results

Labcorp Holdings Inc., a prominent global leader in laboratory services, disclosed robust results for the fourth quarter and full year of 2024, showcasing significant growth across various sectors. The company reported fourth-quarter revenue of $3.33 billion, up from $3.03 billion in the same period last year, marking a substantial 9.8% increase. For the entire year, total revenue reached $13.01 billion, reflecting a growth of 7.0% compared to $12.16 billion in 2023.

Labcorp's CEO, Adam Schechter, attributed this exceptional performance to a combination of organic growth and strategic acquisitions. The company reported diluted earnings per share (EPS) of $1.70 for the fourth quarter, reversing from a loss of $(1.95) in the prior year, while adjusted EPS improved to $3.45 from $3.30. For the full year, the diluted EPS stood at $8.84, more than doubling from $4.33 in 2023, while adjusted EPS also showed significant growth, reaching $14.57 from $13.56.

In terms of financial health, Labcorp's free cash flow for the fourth quarter was $665.1 million, compared to $412.4 million the previous year, and totaled $1.10 billion for the year, indicating a robust 46.5% increase year-over-year from $748.7 million.

Strategic Achievements and Initiatives

Throughout 2024, Labcorp completed 10 transactions and launched various innovative tests addressing unmet medical needs predominantly in oncology, women’s health, neurology, and autoimmune diseases. For example, the company launched a Multiple Sclerosis Monitoring Profile aimed at assessing crucial serum values in patients, and introduced a new molecular diagnostic test for H5 bird flu.

Additionally, Labcorp has enhanced its Labcorp OnDemand test menu to offer more comprehensive health screening and management options for consumers while working to expedite clinical trials through improved technologies.

In light of these accomplishments, Labcorp has set its 2025 revenue guidance between $13.88 billion to $14.05 billion, a midpoint suggesting a growth rate of 7.4%. Adjusted EPS for 2025 is anticipated to range from $15.60 to $16.40, projecting a midpoint growth of 9.8%. The free cash flow is expected to stabilize between $1.10 billion to $1.25 billion, showing an improvement of 7.2%.

Solid Partnerships and Market Expansion

In recent strategic actions, Labcorp acquired select assets from Lab Works in Birmingham, Alabama, and outreach lab services from Ballad Health in the Appalachian region, bolstering its role as a preferred partner for numerous regional hospitals and laboratories. This expansion aims to fortify Labcorp's position amidst growing competition in the lab services space.

A notable partnership was established with New Jersey's Inspira Health to manage laboratory operations and support its physician network, further enhancing Labcorp's market influence in the region.

Financial Overview

At the close of 2024, Labcorp reported a cash balance of $1.52 billion against a debt of $6.33 billion, primed for ongoing investments in acquisitions and technological advancements aimed at boosting operational efficiency and service delivery. The company's proactive approach towards financial management includes a quarterly cash dividend of $0.72 per share, stressing Labcorp's commitment to shareholder value.

In conclusion, Labcorp’s financial results reflect its substantial growth trajectory and strategic advancements within the laboratory services market. With promising guidance for 2025, the company is set to continue its mission of improving patient health and diagnostics worldwide, fulfilling crucial roles within healthcare systems and biopharma laboratory services.